At 28 days post-transplant, when half of the control cohort had to be sacrificed, mice engrafted with Zeb2 interfered leukemia were all alive and showed a significantly lower percentage of GFP+ cells in blood and lower peripheral blood leukocyte counts than controls (respectively 0.3% versus 4.1% GFP+ cells, Figure 3B; and 5.400 versus 11.000 leukocytes/μL, Figure 3C). The gene discussed is ZEB2; the disease is leukemia.